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Abstract 
Introduction: 
Cisplatin is one of the most commonly used antineoplastic drugs; nonetheless, its ototoxic dose-limiting 
side effects have remained a significant challenge in clinical practice. The recognition of the exact 
template of hearing loss induced by multiple low doses of cisplatin could be of great help in managing 
the treatment process. The present study aimed to investigate the effects of multiple doses of this drug 
on the auditory system. 
 
Material and Methods: 
The present study was performed using an experimental guinea pig model in four groups as follows: 
1- 0.9% sodium chloride solution, 2- total dose of 7.5 mg/kg Cisplatin, 3- total dose of 10 mg/kg 
Cisplatin, and 4- total dose of 12.5 mg/kg cisplatin. The drugs were injected as 2.5 mg/kg/daily IP 
access in all groups. The auditory brainstem response (ABR) test was performed before the treatment 
and after every injection on a daily basis up to 72 h after the last injection. 
 
Results: 
There was dose-dependent significant hearing loss in all evaluated frequencies in three cisplatin groups. 
The general template of induced hearing loss during experimental days was almost the same in groups 
Cis7.5 and Cis10. In Cis 12.5 group, there was a jump in the threshold shift on the 5th day of the 
experiment and an upward trend in the function. 
  
Conclusion: 
As evidenced by the obtained results, the monitoring of hearing loss after every injection in patients 
who receive the drug and detecting the exact dose-dependent pattern of the induced hearing loss is of 
great help in controlling its undesirable destructive side effects on the auditory system. 
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Introduction 
American Chemist, Barnett Rosenberg, in 1965 
proved that certain platinum-containing 
compounds inhibit cell division and make 
considerable changes to bacterial morphology 
(1). The antineoplastic property of this newly 
discovered drug which was called cisplatin 
resulted in experimental studies and it eventually 
received food and drug administration (FDA) 
approval in 1978 (2). Nowadays it is a widely 
used anti-cancer drug in multiple cancers, such 
as testicular cancer and ovarian cancer. The 
recovery rate of this drug in testicular cancers is 
higher than 90% (3). Deoxyribonucleic acid 
(DNA) damage in proliferating cells is 
considered to be the primary underlying cause 
of the efficacy of this drug in fighting against 
tumors. Although the rate of cell division in 
most body cells is low or even zero, some cells 
are at higher risk of cisplatin-induced toxicity 
(4,5). This leads to serious side effects, such as 
ototoxicity, nephrotoxicity, and neurotoxicity 
(6-8). Ototoxicity is one of the widely 
recognized side effects of cisplatin treatment. 
Destruction of outer hair cells (OHCs) in the 
organ of Corti by apoptosis is the common 
mechanism of cisplatin ototoxicity (9). This 
process is accomplished by the production of 
free radicals, depletion of glutathione, and 
finally lipid peroxidation. On the other hand, 
reactive oxygen species (ROS) play a key role 
in cisplatin ototoxicity (10).  
Ototoxicity is manifested as bilateral 
progressive and irreversible sensory neural 
hearing loss in most cases (11). More than 60% 
of patients who receive this drug experience 
irreversible hearing loss which exerts a 
destructive impact on their educational and 
psychosocial development (12,13).  
Furthermore, the economic burden of hearing 
loss on society is the leading cause of the 
increasing necessity for finding an applicable 
method for the protection of cochlea against 
cisplatin ototoxicity(14).  
One of the principal considerations in the 
development of conservative methods is 
preventing cisplatin ototoxicity without 
disturbing its anticancer function (15). The 
prevailing suggested and investigated methods, 
such as multiple antioxidants, inhibition of cell 
death route, and the inhibition of inflammation, 
have numerous limitations in clinical practice 
(16-23). They are regarded as invasive methods 
in clinical practice due to the necessity of local 
application to the cochlea or interact with the 
drug in some cases leading to decreased 
antitumor efficacy (24,25).  
Accordingly, the audiological monitoring of 
patients and exerting limitations on drug dosage 
is considered the most appropriate method for 
the protection of cochlea against cisplatin-
induced ototoxicity. The physician must be 
aware of early signs of ototoxicity and its 
progression and could manage to change the 
treatment method if necessary. Therefore, the 
importance of dose-dependent changes in the 
hearing system by cisplatin treatment has been 
highlighted in the literature. With this 
background in mind, the present study aimed to 
daily check the impact of multiple dosages of 
cisplatin on the hearing system of guinea pigs by 
auditory brainstem response. 
 
Material and Methods 
In the present study, albino guinea pigs were 
selected as the laboratory animals for a few 
reasons. They are easy to handle and anesthetic 
infusion and the intraperitoneal (IP) injection of 
the drug are effortless in these animals; 
therefore, they are more sensitive to 
the effects of cisplatin. Animals were obtained 
from Razi Vaccine and Serum Research Institute 
consisting of 24 albino male guinea pigs within 
the weight range of 250-300 grams. Animals 
were kept under standardized housing and 
feeding conditions in separate cages. All of them 
had free access to commercial food and water 
and were maintained in an environment with a 
controlled temperature of 20-25 degrees Celsius 
and 12 h light-dark cycle. The protocol was 
approved by the Institutional Review Board, and 
the animals were handled in accordance with the 
guidelines proposed by the Animal Use 
Committee of the institution. After a 24-hour rest 
and confirming the positive Preyer’s reflex in all 
animals, guinea pigs were assigned to four 
treatment groups (n=6 each) as follows: 
1. The daily IP administration of 0.9% sodium 
chloride solution 2.5 ml/kg  
2. The daily IP administration of cisplatin 
(1mg/ml) 2.5 mg/kg  for three consecutive days 
(total dose of 7.5 mg/kg) (Cis7.5) 
3. The daily administration of cisplatin 
(1mg/ml) 2.5 mg/kg  for four consecutive days 
(total dose of 10 mg/kg) (Cis10) 
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4. The daily IP administration of cisplatin 
(1mg/ml) 2.5 mg/kg for five consecutive days 
(total dose of 12.5 mg/kg) (Cis12.5) 
For the controlled application of drugs, we 
used 1 cc disposable insulin syringe for each 
animal. 
Auditory Brainstem Response (ABR) test was 
performed using an electrophysiologic system 
(Biologic/Navigator pro, USA). The test was 
carried out before the treatment (baseline 
measurement) and after every injection on a 
daily basis. The injections were daily performed 
at 7 am and the hearing assessments were carried 
out at 7 pm. The hearing evaluation was 
continued up to 72 h after the last injection. The 
guinea pigs were anesthetized by intraperitoneal 
injection of a mixture of ketamine 40 mg/kg and 
xylazine 4 mg/kg. While ABR tests were 
performed, the body temperature was 
maintained at 36°C with an electric blanket 
controlled by a rectal thermistor. In the pilot 
study, it was confirmed that cisplatin induces 
bilateral and symmetrical hearing loss. 
Consequently, it was required to avoid data 
duplication and consider inter-subject variability 
factors. In this regard, the test was performed 
using a far-field technique from the right ears of 
all animals, and the left ear was blocked by an 
earplug during the test. The reference electrode 
was subcutaneously inserted into the ipsilateral 
pinna, the ground electrode into the contralateral 
pinna, and the active electrode into the top of the 
head. Before the commencement of the test, the 
impedance of electrodes was confirmed to be 
below 5 k Ohms. Acoustic stimuli were 
delivered by a far-field speaker in a sound-proof 
box, and the sound levels within the 
animal hearing range were calibrated with a 
sound level meter. Acoustic stimuli consisted of 
tone-bursts of 4, 8, 12, and 16 kHz (the total 
duration was 10 ms, and the rise and fall times 
were 2 ms). The result of the time window 
analysis for each response was 10.66 ms. The 
evoked potentials were filtered with a band-pass 
filter between 100 and 3000 Hz. The stimulus 
presentation rate was 23.1 bursts of alternating 
polarity per second. The minimum number of 
sweeps was reported as 1024, and the gain was 
adjusted at 100k.In evaluating the hearing 
thresholds, the stimuli levels were lowered from 
80 in 5-dB steps until the identification of a 
visible repeatable wave III. The recordings were 
repeated twice at the threshold level for 
confirming the reproducibility of the waves. 
Wave III was used for the detection of 
thresholds. 
The obtained data were analyzed in SPSS 
software (version 17) using repeated measures. 
The quantitative data were presented as 
mean±SD. A p-value less than 0.05 was 
considered statistically significant. 
 
Results 
The total change in ABR thresholds (last 
measurement-baseline measurement) in four 
different groups are displayed in Figure1. In all 
groups, cisplatin induced significant changes in 
ABR thresholds at all frequencies. The mean 
threshold shifts (Mean±SD) in group Cis7.5 
were measured at 14.16±7.35 dB at 4 kHz 
(P=0.005), 14.21±7.20 dB at 8KHz(P=0.005), 
15.00±7.07 dB at 12 kHz(P=0.003), and 
15.24±7.02 dB at 16 kHz (p=0.003). In group 
Cis10, the mean threshold shifts were obtained 
at 22.50±6.89 dB (P=0.000) in 4 kHz, 
23.33±6.83 dB (P=0.000) in 8 kHz, 
25.00±10.00 dB (P=0.002) in 12 kHz, and 
25.83±5.84 dB (P=0.000) in 16 kHz. The mean 
ABR threshold shifts in group Cis12.5 were 
calculated at 55.33±6.83 dB (P=0.000) in 4 
kHz, 55.00±5.47 dB (P=0.000) in 8 kHz, 
56.83±4.91 dB (P=0.000) in 12 kHz, and 
57.50±4.18 dB (P=0.000) in 16 kHz. In the 
control group, no significant change was 
observed in mean ABR threshold shifts 
between the last measurement and the baseline 
values. The changes were 1.66±2.58 dB 
(P=0.175) in 4 kHz, 2.50±6.89 dB (P=0.415) in 
8 kHz, -0.83±6.64 dB(P=0.771) in 12 kHz, and 
2.50±5.24 dB(P=0.296) in 16 kHz. 
 
Fig 1: Mean auditory brainstem response 
threshold shifts (dB) in different frequencies in 
four experimental groups 
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The mean of ABR thresholds(dB) within 8 
experiment days for all four groups is depicted 
in figures 2, 3, 4 and 5, for 4 kHz, 8 kHz, 12 
kHz, and 16 kHz tones, respectively. The 
changes in ABR thresholds during the 
experiment days are statistically significant in 
all groups which received cisplatin (Cis7.5, 
Cis10, and Cis12.5) (Table.1). 
 
Fig 2: Mean auditory brainstem response  thresholds 
(dB) in experimental days in 4kHz 
 
Fig 3: Mean auditory brainstem response  thresholds(dB) 
in experimental days in 8kHz 
 
Fig 4: Mean auditory brainstem response thresholds (dB) 
in experimental days in 12 kHz 
 
 
Fig 5: Mean auditory brainstem response thresholds (dB) 
in experimental days in 16 kHz 
 
Table1: Mean auditory brainstem response thresholds (dB) for 4 kHz, 8 kHz, 12 kHz, and 16 kHz tones in all 
groups in 8 experiment days. 
frequency  Mean auditory brainstem response thresholds(dB)±SD  
P-value 
Experiment days 
  0 1 2 3 4 5 6 7 8  
4(kHz) Group Control 24.5±4.18 24.50±6.12 23.66±6.05 23.66±4.08 24.50±6.12 25.33±6.83 24.50±6.12 26.66±6.37 26.16±4.91 0.94 
Cis7.5 26.16±3.76 28.66±7.52 30.33±8.16 36.16±5.84 37.83±3.76 39.50±5.24 40.33±6.05 40.33±6.05 4.33±6.05 0.00 
Cis10 24.50±2.73 26.16±3.76 28.66±6.05 34.50±6.89 41.16±10.68 44.50±9.35 46.16±7.35 47.00±7.07 47.00±7.07 0.00 
Cis12.5 26.16±2.04 27.83±2.04 29.50±4.18 34.50±5.24 41.16±8.61 62.00±7.74 73.66±6.83 77.00±7.74 79.50±6.89 0.00 
8(kHz) group control 24.00±3.16 24.83±3.76 24.00±3.16 26.50±6.12 25.66±4.08 26.50±4.18 26.50±4.18 25.66±5.16 26.50±5.24 0.79 
Cis7.5 24.00±4.47 26.50±6.89 28.16±5.84 34.83±3.76 35.66±4.08 37.33±2.58 38.16±3.76 38.16±3.76 38.16±3.76 0.00 
Cis10 23.16±3.76 24.83±3.76 26.50±2.73 32.33±5.16 39.00±4.47 43.16±4.91 45.66±5.16 46.50±5.24 42.83±9.70 0.00 
Cis12.5 24.83±4.91 26.50±5.24 28.16±3.76 34.00±4.47 41.50±2.73 62.33±5.16 73.16±2.04 77.33±5.16 76.33±5.53 0.00 
12(kHz) group control 17.83±4.91 16.16±5.84 17.00±7.07 16.16±5.84 17.83±3.76 15.33±2.58 16.16±5.84 15.33±6.83 17.00±8.36 0.97 
Cis7.5 17.00±5.47 18.66±4.08 21.16±4.91 27.00±5.47 29.50±4.18 31.16±4.91 32.00±4.47 32.00±4.47 32.00±4.47 0.00 
Cis10 17.83±2.04 19.50±2.73 21.16±3.76 27.00±4.47 35.33±4.08 40.33±5.16 41.16±5.84 42.83±9.70 42.83±9.70 0.00 
Cis12.5 19.50±2.73 21.16±3.76 22.83±3.76 28.66±5.16 37.00±6.32 58.61±7.52 70.33±5.16 75.33±5.16 76.33±5.53 0.00 
16(kHz) group control 8.83±4.91 9.66±2.58 9.66±4.08 10.50±5.24 9.66±2.58 10.50±4.18 10.50±4.18 10.50±6.89 11.33±4.08 0.97 
Cis7.5 8.83±3.76 10.50±2.73 12.16±3.76 18.83±5.84 21.33±4.08 23.00±4.47 23.83±3.76 23.83±3.76 23.83±3.76 0.00 
Cis10 8.83±4.91 10.50±2.73 12.16±3.76 18.00±6.32 26.33±8.75 32.83±4.49 33.50±5.57 33.83±6.64 33.83±6.64 0.00 
Cis12.5 9.66±4.08 11.33±2.58 13.83±2.04 18.83±7.35 26.33±8.16 48.83±12.41 60.50±7.58 65.50±8.21 67.16±5.84 0.00 
Cisplatin Ototoxicity 
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Discussion 
A wide spectrum of unpleasant effects on the 
inner ear, including hearing loss, tinnitus and 
vertigo have been reported for some drugs, such 
as cisplatin (26). For many years, researchers 
all over the world have sought to recognize the 
basis and pattern of the inner ear impairment in 
an effort to propose some strategies for the 
prevention and control of side effects. 
Cisplatin-induced hearing loss, apart from 
studies on patients who receive this drug(27), is 
investigated in numerous experimental 
animals, such as rats(28,29) and guinea-
pigs(17,30,31). According to these studies, 
cisplatin induces dose-dependent bilateral 
sensorineural hearing loss(32). In the present 
study, three different doses of this drug (7.5, 10, 
and 12.5 mg/kg) were used as daily injections 
of 2.5 mg/kg in guinea-pigs for 3, 4, and 5 
consecutive days to identify the detailed 
template of the damage. Daily threshold 
changes of ABR were used as a functional 
marker for cochlear impairment. As illustrated 
in Figure1, the total dose of 7.5 mg/kg cisplatin 
has induced a mean threshold shift of 14.65 dB 
in four evaluated frequencies (4 kHz, 8 kHz, 12 
kHz, and 16 kHz). With increasing the 
administered dose to 10 and 12.5 mg/kg, the 
mean threshold shift values reached 24.16 dB 
and 56.16 dB, respectively. This finding is 
consistent with the previously published results 
verifying the cumulative essence of cisplatin-
induced hearing loss. Liba et al. (2017) 
observed median ABR threshold changes of 15 
dB by single low-dose cisplatin treatment 
(8mg/kg). The changes in ABR thresholds are 
comparable to our observed changes in mean 
ABR thresholds by using the total dose of 7.5 
mg/kg cisplatin (33). Xiong et al. (2011) 
investigated the role of nitric oxide in cisplatin 
ototoxicity.  In the mentioned study, 72 h after 
the injection of 10 mg/kg cisplatin in guinea 
pigs, 22.3 dB and 26.8 dB changes were 
observed in mean ABR thresholds at 8 kHz and 
16 kHz tones, respectively (34). Using the same 
dose of the drug in guinea pigs, very similar 
results were obtained, including a 23.33 dB 
shift in mean ABR thresholds in 8 kHz and 
25.83 dB changes in 16 kHz. Murphy et al. 
(2011) carried out a study to investigate the role 
of intratympanic dexamethasone in the 
prevention of cisplatin-induced hearing loss. 
They indicated mean ABR threshold shift of 
23.4 dB by total dose of 10 mg/kg and 57.2 dB 
shifts by total dose of 12 mg/kg cisplatin in 
guinea pigs(35). On the other hand, the 
administration of the single dose of 12mg/kg 
cisplatin in guinea pigs resulted in 55 dB shifts 
at 8 kHz tone and 51 dB shift at 16 kHz tone, in 
the study conducted by Waissbluth et al. 
(2012)(36). There are a number of articles in 
this category with nearly the same results 
confirming the cumulative effects of multiple-
low dose IP injection on the hearing system. 
Nevertheless, it is noteworthy that there is no 
linear relationship between the total dose of the 
drug and the resulted hearing loss. In other 
words, by increasing just one low-dose 
injection from 10 mg/kg to 12.5 mg/kg, the 
changes in the hearing threshold remarkably 
increase. In the present study, we evaluated and 
recorded the resultant daily increase in mean 
ABR thresholds in order to exactly analyze the 
template of these increases and obtain some 
valuable results. As depicted in Figure 2, the 
patterning of the threshold change is the same 
in all groups until the 3rd day of experiment. In 
group Cis7.5, which received the drug up to the 
3rd day, the diagram of threshold elevation 
grows by a gradual slope in the next days. In 
group Cis10, there is another rising step almost 
identical with the recent increases; thereafter, 
the graph rises almost as slightly as the Cis7.5 
group at the 4th day of experiment. In group 
Cis12.5, following the last injection on the 5th 
day, there is a sharp surge in the graph 
demonstrating an upward trend during the next 
days. This trend leads to a total threshold 
change of 56.16 dB in mean ABR thresholds in 
72 h after the last injection on the 8th day. From 
a clinical perspective, finding such a 
momentous dose could be of great help in 
governing the ototoxicity symptoms. Previous 
studies have reported that above a certain 
critical cumulative dose of the drug in the 
blood, the destruction increases very rapidly. 
This occurs as the result of permanent renal 
damage leading to the accumulation of the drug 
in the blood (37). 
The results of the current study highlighted the 
importance of daily evaluation of the auditory 
system in patients who receive this drug. The 
recognition of the template of this degeneration 
could be of significant importance for the 
avoidance of undesirable side effects of this 
drug. On the other hand, daily monitoring of the 
hearing system is definitely an inexpensive and 
cost-effective strategy, as compared to the 
Salehi N, et al 
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adverse effects of hearing loss on patients who 
receive the drug, especially children. It is worth 
mentioning that in humans, the exact pattern of 
induced hearing loss and the dose of the drug 
which causes ototoxicity is not as identical as it 
is in experimental animals(38).  
 
Conclusion 
On a final note, in the light of the obtained 
findings of the present study and the results 
reported in the literature, it can be concluded 
that the recognition of the template of this 
degeneration could be of significant importance 
for the avoidance of undesirable side effects of 
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